Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Autograft Clear all
Recruiting Phase 1 Interventional

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

NCT02917083
View directory record Official record
Conditions
Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
Interventions
CAR T Cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2040
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma

NCT00225212
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma, Transformed Lymphoma, Other Subtypes of B-cell Lymphoma, Lymphoma
Interventions
Rituximab 375 mg/m2
Drug
Lead sponsor
Stanford University
Other
Eligibility
16 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2014 · Synced Sep 15, 2026, 10:43 AM EDT
Recruiting Not applicable Interventional

Comparison of Iliac Crest Marrow vs. Proximal Tibia Avitus® Bone Graft

NCT07434505
View directory record Official record
Conditions
Bone Graft
Interventions
Avitus Bone Harvester
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Not applicable Interventional Results available

RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction

NCT04091672
View directory record Official record
Conditions
Full-thickness Skin Defects, Degloving Injuries, Crush Injuries, Laceration of Skin, Surgical Wound, Skin Cancer, Cellulitis, Infection, Necrotizing Fasciitis, Gun Shot Wound
Interventions
Control Intervention (Conventional Autograft), Investigational Intervention (RECELL + more widely meshed autograft)
Procedure · Device
Lead sponsor
Avita Medical
Industry
Eligibility
5 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 15, 2026, 10:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns

NCT04765202
View directory record Official record
Conditions
Full Thickness Thermal Burn
Interventions
AG Tx, SOMA Tx
Procedure · Biological
Lead sponsor
Stratatech, a Mallinckrodt Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 15, 2026, 10:43 AM EDT
Recruiting No phase listed Observational

Taking Measurements of a Gum Graft Site as it Heals

NCT07386457
View directory record Official record
Conditions
Gingival Recession
Interventions
Gingival graft surgery to treat gingival recession
Procedure
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM

NCT03630289
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, GBM, Brain Cancer
Interventions
Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

NCT00103662
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Granulocyte colony-stimulating factor plus plerixafor, Granulocyte colony-stimulating factor plus placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 78 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
37
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

NCT02322320
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
42
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 15, 2026, 10:43 AM EDT
Not listed Phase 2 Interventional

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

NCT03570983
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Allopurinol, Carmustine, Etoposide, Cytarabine, Melphalan
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 15, 2026, 10:43 AM EDT
Recruiting Not applicable Interventional

MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion

NCT05037968
View directory record Official record
Conditions
Degenerative Disc Disease, Spine Fusion, Leg Pain and/or Back Pain
Interventions
MagnetOs Flex Matrix, Trinity Elite
Device
Lead sponsor
Kuros Biosurgery AG
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Hartford, Connecticut • Chicago, Illinois • Columbia, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 1 Interventional Results available

Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma

NCT02148913
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cohort 1: Carfilzomib 15 mg/m2, Cohort 2: Carfilzomib 20 mg/m2, Cohort 2b: Carfilzomib 20 mg/m2, Cohort 3b: Carfilzomib 27 mg/m2
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

NCT00472056
View directory record Official record
Conditions
Lymphoma
Interventions
Carmustine, Etoposide, Cytarabine, Melphalan, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 80 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Not applicable Interventional

The Use of RIA to Harvest Bone Graft for Treatment of Non-unions and Fractures

NCT00582439
View directory record Official record
Conditions
Orthopaedic Trauma Fractures and Non-unions
Interventions
Reamer-Irrigator-Aspirator (RIA)
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Sep 15, 2026, 10:43 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair

NCT02480777
View directory record Official record
Conditions
Sciatic Nerve Injury
Interventions
Autologous Human Schwann cells
Biological
Lead sponsor
W. Dalton Dietrich
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 2 Interventional Results available

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

NCT02728102
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Tumor Cell Collection, Autologous Stem Cell Transplant, Melphalan, Leukapheresis, Myeloma vaccine, GM-CSF, Lenalidomide
Procedure · Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 15, 2026, 10:43 AM EDT
Active, not recruiting No phase listed Observational

Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

NCT02698579
View directory record Official record
Conditions
Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD), X-Linked Adrenoleukodystrophy (X-ALD)
Interventions
No interventional drug product utilized in this follow-up study
Genetic
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
Up to 19 Years · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2038
U.S. locations
4
States / cities
Los Angeles, California • Palo Alto, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 15, 2026, 10:43 AM EDT
Active, not recruiting Not applicable Interventional

Adaptix RCT Evaluating Adaptix™ Versus PEEK Cages

NCT05182489
View directory record Official record
Conditions
Spinal Canal Stenosis, Spondylolisthesis, Osteophyte, Bony Growth Formation, Degenerative Disc Disease
Interventions
Medtronic Adaptix™ titanium implants, Medtronic CAPSTONE® PEEK cage
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Not applicable Interventional Results available

Prevention of Oral Mucositis Using Photobiomodulation Therapy

NCT04227340
View directory record Official record
Conditions
Oral Mucositis
Interventions
Photobiomodulation Therapy (PBM), Pain and Oral Function Assessment, Parent-Reported Satisfaction Survey
Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 15, 2026, 10:43 AM EDT
Active, not recruiting No phase listed Observational

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

NCT02633943
View directory record Official record
Conditions
Transfusion-dependent Beta-Thalassemia
Interventions
Safety and efficacy assessments
Other
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
0 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2035
U.S. locations
6
States / cities
Oakland, California • Chicago, Illinois • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 15, 2026, 10:43 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Healos as a Bone Replacement to Treat Degenerative Disc Disease

NCT00316121
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
HEALOS and Leopard Cage, Leopard Cage and Autograft
Device
Lead sponsor
Advanced Technologies and Regenerative Medicine, LLC (ATRM)
Other
Eligibility
18 Years to 70 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
17
States / cities
Little Rock, Arkansas • Beverly Hills, California • Brandon, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Sep 15, 2026, 10:43 AM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Sinus Augmentation Bone Healing Using Autograft and Xenograft Compared to Xenograft Alone

NCT06247098
View directory record Official record
Conditions
Maxillary Sinus Floor Augmentation, Dental Implant, Bone Substitute, Autogenous Bone Graft
Interventions
Sinus Lift augmentation, Cone-beam computed tomography systems (CBCT)
Procedure · Device
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 15, 2026, 10:43 AM EDT
Completed No phase listed Observational Results available

Continued Access to the Recell® Device for Treatment of Acute Burn Injuries

NCT03333941
View directory record Official record
Conditions
Burns
Interventions
ReCell® Autologous Cell Harvesting Device
Device
Lead sponsor
Avita Medical
Industry
Eligibility
5 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 15, 2026, 10:43 AM EDT
Recruiting Not applicable Interventional

Quadriceps Tendon Versus Bone Patellar Tendon Bone Autograft ACL Reconstruction RCT

NCT05461326
View directory record Official record
Conditions
Orthopedic Disorder, Anterior Cruciate Ligament Injuries
Interventions
Quad tendon, BTB
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 15, 2026, 10:43 AM EDT